Implementing ESG principles in pharma industry in emerging markets

Abstract

The implementation of Environmental, Social, and Governance (ESG) principles in the pharmaceutical industry within emerging markets presents both a significant challenge and a valuable opportunity for sustainable development. Given the crucial role of this sector in public health, adopting ESG practices can substantially influence not only the industry's environmental footprint but also its social and governance responsibilities. In emerging markets, where regulatory frameworks may be less stringent compared to developed economies, the pharmaceutical industry often operates under increased scrutiny. Therefore, alignment with global ESG standards is essential for companies aiming to enhance competitiveness, attract investment, and meet the rising expectations of stakeholders. This study focuses on the Serbian pharmaceutical sector and employs a mixed-method approach, combining semi-structured interviews and focus groups to assess the extent of ESG adoption. The findings reveal that while some companies have partially integrated ESG principles into their operations, others have not adopted them at all. Key challenges, such as limited financial resources, diverse regulatory frameworks, and potential resistance to change, hinder widespread ESG implementation. However, the long-term benefits of ESG compliance including improved reputation, better risk management, and financial sustainability, underscore the importance of these principles for companies in this sector. Environmental aspects are leading concern, such as waste reduction, carbon footprint minimization through sustainable supply chains, and proper disposal of pharmaceutical products remain crucial.